Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.18%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.57 per share when it actually produced a loss of $0.48, delivering a surprise of 15.79%.Over the last four quarte ...

Revenue Performance - Total revenue for Q3 2024 was $191.5 million, a 34% increase from $143.0 million in Q3 2023[10] - Precision oncology testing revenue reached $180.6 million, up 35% from $133.4 million year-over-year[10] - Total revenue for the three months ended September 30, 2024, was $191.5 million, an increase of $48.4 million, or 34%, compared to $143.0 million for the same period in 2023[185] - Precision oncology testing revenue increased to $180.6 million for the three months ended September 30, 2024, from $133.4 million for the same period in 2023, representing a growth of $47.2 million, or 35%[185] - Total revenue for the nine months ended September 30, 2024, was $537.2 million, an increase of $128.3 million, or 31%, compared to $408.9 million for the same period in 2023[201] Financial Losses - Net loss for Q3 2024 was $107.8 million, compared to a net loss of $86.1 million in Q3 2023[12] - The company reported a comprehensive loss of $105.4 million for Q3 2024, compared to a comprehensive loss of $83.3 million in Q3 2023[12] - Net loss for the three months ended September 30, 2024, was $(107.8) million, compared to $(86.1) million for the same period in 2023[182] - Net loss for the nine months ended September 30, 2024, was $325,367, compared to a net loss of $292,406 for the same period in 2023, representing an increase of approximately 11.3%[20] - Net losses for Q3 2024 were $107.8 million, compared to $86.1 million in Q3 2023, indicating a 25.3% increase in losses[154] Assets and Liabilities - Total current assets decreased to $1.23 billion as of September 30, 2024, down from $1.35 billion at the end of 2023[8] - Cash, cash equivalents, and restricted cash decreased to $688.4 million from $1.13 billion at the end of 2023[8] - Total liabilities decreased to $1.60 billion as of September 30, 2024, from $1.63 billion at the end of 2023[8] - Total stockholders' equity as of September 30, 2024, was $158,684, down from $228,299 as of September 30, 2023, indicating a decrease of about 30.5%[18] - Cash, cash equivalents, and marketable securities totaled approximately $1.0 billion as of September 30, 2024[154] Expenses - Research and development expenses for Q3 2024 were $87.3 million, slightly down from $93.9 million in Q3 2023[10] - Sales and marketing expenses increased to $97.9 million in Q3 2024, compared to $68.9 million in Q3 2023[10] - Total costs and operating expenses for the three months ended September 30, 2024, were $308.8 million, compared to $256.6 million for the same period in 2023[182] - General and administrative expenses for the three months ended September 30, 2024, were $49.1 million, compared to $36.2 million for the same period in 2023[182] - Research and development expenses for the three months ended September 30, 2024, were $18.6 million, up from $8.5 million in the same period in 2023, reflecting a significant investment in innovation[130] Stock-Based Compensation - Stock-based compensation for the nine months ended September 30, 2024, was $104,045, significantly higher than $66,439 for the same period in 2023, marking a rise of about 56.5%[20] - The company recorded a cumulative stock-based compensation expense of $23.5 million in Q3 2024 related to performance-based restricted stock units (PSUs)[126] - Future stock-based compensation for unvested restricted stock units as of September 30, 2024 is estimated at $119.1 million, expected to be recognized over 2.0 years[124] - The company recognized total stock-based compensation expense of $49.8 million for the three months ended September 30, 2024, compared to $21.8 million in the same period of 2023[130] - Stock-based compensation recorded for PSUs was $22.7 million for Q3 2024, compared to $0.8 million for Q3 2023[127] Product Development and Launches - The company launched the Shield blood test for colorectal cancer screening, which received FDA approval in July 2024 and became commercially available in August 2024[23] - The Guardant360 LDT and Guardant360 CDx tests are now being used as companion diagnostics for non-small cell lung cancer and breast cancer, enhancing the company's product offerings in precision oncology[22] - The company has developed the GuardantINFORM platform to assist biopharmaceutical companies in accelerating precision oncology drug development[22] - The Shield blood test demonstrated 83% sensitivity and 90% specificity in detecting colorectal cancer, exceeding CMS performance criteria[162] - The Guardant360 CDx test received ADLT status from CMS, leading to increased reimbursement rates effective January 1, 2022[158] Market and Customer Insights - For the three months ended September 30, 2024, Customer B represented 28% of total revenue, down from 33% in the same period of 2023[39] - Precision oncology revenue from clinical tests covered by Medicare was approximately 38% in Q3 2024, down from 45% in Q3 2023[155] - Precision oncology revenue from clinical customers was $141.2 million for the three months ended September 30, 2024, up 36% from $103.9 million for the same period in 2023, driven by increased sample volume and reimbursement[186] - Total tests for clinical customers increased to approximately 53,100 for the three months ended September 30, 2024, from approximately 43,900 for the same period in 2023[186] - Precision oncology revenue from biopharmaceutical customers was $39.4 million for the three months ended September 30, 2024, up 34% from $29.5 million for the same period in 2023, primarily due to increased sample volume[187] Compliance and Legal Matters - The company recorded a liability of $83.4 million in Q4 2023 due to a jury verdict for willful infringement of patents, resulting in a 6% royalty on past sales[110] - The company has entered into a Collaboration Agreement with Illumina to advance cancer research and dismissed a prior lawsuit with prejudice[111] - The company is seeking an injunction and compensatory damages in a patent infringement suit against Tempus AI, Inc.[112] Future Outlook - The Company expects to recognize substantially all of the remaining transaction price allocated to performance obligations in the next 1-2 years, indicating a strong revenue pipeline[59] - The company expects to expand into lung and multi-cancer screening with the next-generation Shield assay[151] - The company signed a partnership with Agostino Gemelli University Polyclinic Foundation IRCCS in September 2024 to establish liquid biopsy testing services in Italy[164]

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 PALO ALTO, Calif. November 6, 2024 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights • Recorded revenue of $191.5 million fo ...

Wall Street analysts forecast that Guardant Health (GH) will report quarterly loss of $0.55 per share in its upcoming release, pointing to a year-over-year increase of 24.7%. It is anticipated that revenues will amount to $169.87 million, exhibiting an increase of 18.8% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 1.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration o ...

There's nothing like free publicity to help goose the sales of a relatively new product. Cancer-diagnostics specialist Guardant Health (GH 5.87%) was a standout in the biotech sector on Hump Day. Investors cheered the company's news that one of its products made it onto a list of top innovations compiled by a familiar magazine. In response, they traded Guardant's shares up by almost 6%, making it quite the outperformer when matched against the S&P 500 index's 0.3% drop on the day. One of the top innovations ...

Guardant Health (GH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Nove ...

Guardant Health needs cash. Until it can get it from selling enough services, it must sell its own shares instead. Shares of precision medicine company Guardant Health (GH -11.13%), which specializes in liquid biopsies to test for cancer, fell 10.6% through 10:05 a.m. ET Monday morning. Monday was the first trading day in which investors got to react to a Guardant announcement late Friday, that it plans to sell stock and raise $400 million in new cash to fund its operations. Guardant needs money Guardant's ...

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. The 20-day moving ...

| --- | --- | --- | |----------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Transforming Cancer Care Q2 2024 Earnings Call August 7, 2024 | | | Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve know ...

Guardant Health, Inc. (NASDAQ:GH) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Jack Meehan - Nephron Research ...